Lenzilumab
- Generic Name
- Lenzilumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1229575-09-0
- Unique Ingredient Identifier
- IE4X6497XK
- Background
Lenzilumab is under investigation in clinical trial NCT02546284 (Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)).
- Associated Conditions
- -
- Associated Therapies
- -
Cytokine Release Syndrome and Neurotoxicity After CAR T-Cell Therapy
CAR T-cell therapy toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), are common and range from mild to severe. CRS is managed with corticosteroids and tocilizumab, while ICANS requires supportive care and corticosteroids. Emerging treatments like anakinra and itacitinib show promise in managing these toxicities.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath